Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

TCGA-62-A46V-01A-11R-A24H-07

· cohortA1

6c09b20c-ce39-57b0-8740-aa5ed6255c29

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortA1
subtype
cohortA1
age_years
78

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • COAGULATION+0.210
  • MYOGENESIS+0.210
  • FATTY_ACID_METABOLISM+0.180
  • PEROXISOME+0.150
  • BILE_ACID_METABOLISM+0.120
  • ADIPOGENESIS+0.110
  • XENOBIOTIC_METABOLISM+0.110
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.060
  • APICAL_JUNCTION+0.050
  • PANCREAS_BETA_CELLS+0.040

Top 10 suppressed

  • E2F_TARGETS-0.470
  • G2M_CHECKPOINT-0.440
  • MYC_TARGETS_V2-0.430
  • TGF_BETA_SIGNALING-0.410
  • INTERFERON_GAMMA_RESPONSE-0.400
  • TNFA_SIGNALING_VIA_NFKB-0.400
  • ALLOGRAFT_REJECTION-0.390
  • MYC_TARGETS_V1-0.390
  • INFLAMMATORY_RESPONSE-0.350
  • MTORC1_SIGNALING-0.350

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-97-8179-01A-11R-2287-07
lung-landscapes@6
cohortA20.843
2TCGA-78-7149-01A-11R-2039-07
lung-landscapes@6
cohortA20.840
3SJEPD001522_R1.RNA-Seq
medullo-epn-umap@date-based
EPNEPN Tumor0.838
4MBCProject_3946_T4_RNA
breast-umap@18
A0.833
5SRR2700736
melanoma-umap@29
0.832
6TCGA-NJ-A55R-01A-11R-A262-07
lung-landscapes@6
cohortA30.821
73d1f44d8-6084-47cb-b57b-099f2cd1fa0e
melanoma-umap@29
0.819
8C3L-03726
lung-landscapes@6
cohortA20.818
9SRR1313097
breast-umap@18
A0.816
10SRR12202450
bladder-landscape@3
0.815

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 10 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
COAGULATION0.210Binimetinib— uncovered
MYOGENESIS0.210Inavolisib— uncovered
FATTY_ACID_METABOLISM0.180Inavolisib— uncovered
PEROXISOME0.150Idelalisib— uncovered
BILE_ACID_METABOLISM0.120Inavolisib— uncovered
ADIPOGENESIS0.110Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.110Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.060Inavolisib— uncovered
APICAL_JUNCTION0.050Inavolisib— uncovered
PANCREAS_BETA_CELLS0.040Cobimetinib— uncovered